相关实验视频

Updated: Jun 25, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

在卡斯特曼病的免疫学和向治疗

Shinichiro Tsunoda¹, Takuya Harada^2,3, Yoshikane Kikushige^2,4

¹Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Sumitomo Hospital, Osaka, Japan.

Expert review of clinical immunology

|May 24, 2024

概括

卡斯特曼病 (CD) 涉及全身炎症. 对抗IL-6抑制剂的多中心性CD (MCD) 病例需要新的治疗方法,Tph细胞向疗法显示出有前途.

科学领域:

血液学血液学血液学
免疫学免疫学免疫学
在瘤学瘤学.

背景情况:

卡斯特曼病 (CD) 是一种与严重的全身炎症相关的良性淋巴增殖性疾病.
多中心卡斯特曼病 (MCD) 病原体涉及IL-6,但IL-6抑制剂仅在30%-60%的患者中有效.
对于对IL-6抑制剂耐药性MCD病例的新型治疗剂有着显著的未满足的需求.

研究的目的:

审查CD的病理和临床分类.
为了确定异形性MCD (iMCD) 的治疗点.
总结目前和新兴的IMCD治疗候选药物.

主要方法:

在CD.中对临床数据和病理发现的审查.
分析涉及到MCD病变的信号通路,包括JAK/STAT和PI3K/Akt/mTOR.
研究涉及外围辅助T (Tph) 细胞及其产物的新途径.

主要成果:

异形性MCD (iMCD) 病原发生涉及JAK/STAT和PI3K/Akt/mTOR通路.
iMCD-TAFRO亚型表现出对IL-6抑制剂的耐药性;环素和mTOR抑制剂可能提供益处.
外围辅助T (Tph) 细胞异常和Tph-CXCL13-B细胞轴是iMCD病原体的核心.

结论:

雅克抑制剂和mTOR抑制剂是iMCD的潜在治疗药物.
针对Tph细胞-CXCL13通路为耐火性iMCD病例提供了一个有希望的策略.
进一步阐明CD的发病因子对于开发有效治疗方法至关重要.

关键词:

在CXCL13中,CXCL13是最重要的.卡斯特曼病是什么?卡斯特曼病是什么?在IL-6的研究中,IL-6被认为是IL-6的基因.这就是JAK-STAT.在TAFRORO中,我们有很多机会.在iMCD上使用iMCD.在mTOROR中使用mTOR.周围的辅助T细胞

更多相关视频

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...